An observational study in Migraine, sponsored by Cefaly Technology. Completed. Per ClinicalTrials.gov, last updated 2017-05-08.
Sponsored by Cefaly Technology · Observational
This is an Internet survey to collect data on the use of the Cefaly device to treat migraine attacks in regular Cefaly users.
About 1000 CEFALY users, having the device since more than one year and having reordered electrodes in the last year, will be invited to participate to an Internet survey. This survey contains at most 8 questions, and data will be collected completely anonymously. Questions concern the use or not of the CEFALY during migraine attacks, the number of treated attacks and the number and type of acute anti-migraine drugs that were avoided thanks to the use of the CEFALY.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 807 is above the median of 130 across 299 observational studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Cefaly Technology is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
French speaking patients in Belgium, Switzerland and France, having ordered new electrodes during the last year will be identified as regular users.
Exclusion Criteria:
Monthly number of acute drug intake avoided when using Cefaly to treat a migraine attack
On average, mean number of anti-migraine acute drug intake avoided per month per patient in regular Cefaly users, based on self reported average monthly number of attacks and percentage of attacks treated successfully with the Cefaly
Time frame: Maximum 1 year
Proportion of Cefaly users that report using also the device to treat migraine attacks
Percentage of regular Cefaly users using the device to treat attacks
Time frame: Maximum 1 year
Proportion of migraine attacks treated with the Cefaly device
Percentage of migraine attacks treated with the Cefaly device by the Cefaly users
Time frame: Maximum 1 year
Proportion of migraine attacks for which the use of the Cefaly device generate a reduction of drug intake
Percentage of migraine attacks treated with the Cefaly device and for which the acute anti-migraine drug intake is reduced thanks to the Cefaly
Time frame: Maximum 1 year
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cefaly Technology